ATE256143T1 - 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen - Google Patents
2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungenInfo
- Publication number
- ATE256143T1 ATE256143T1 AT93917287T AT93917287T ATE256143T1 AT E256143 T1 ATE256143 T1 AT E256143T1 AT 93917287 T AT93917287 T AT 93917287T AT 93917287 T AT93917287 T AT 93917287T AT E256143 T1 ATE256143 T1 AT E256143T1
- Authority
- AT
- Austria
- Prior art keywords
- phosphoramidites
- production
- alkyl
- alkyl nucleosides
- guanosine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000002777 nucleoside Substances 0.000 title 1
- 150000008300 phosphoramidites Chemical class 0.000 title 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 3
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 abstract 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 abstract 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 2
- 229940029575 guanosine Drugs 0.000 abstract 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 abstract 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 abstract 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 abstract 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 1
- 229940045145 uridine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/918,362 US5506351A (en) | 1992-07-23 | 1992-07-23 | Process for the preparation of 2'-O-alkyl guanosine and related compounds |
| US07/967,267 US7101993B1 (en) | 1990-01-11 | 1992-10-27 | Oligonucleotides containing 2′-O-modified purines |
| US96884992A | 1992-10-30 | 1992-10-30 | |
| PCT/US1993/006807 WO1994002501A1 (en) | 1992-07-23 | 1993-07-20 | Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE256143T1 true ATE256143T1 (de) | 2003-12-15 |
Family
ID=27420643
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93917287T ATE256143T1 (de) | 1992-07-23 | 1993-07-20 | 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen |
| AT02076058T ATE299509T1 (de) | 1992-07-23 | 1993-07-20 | Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02076058T ATE299509T1 (de) | 1992-07-23 | 1993-07-20 | Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP0651759B1 (de) |
| JP (3) | JP3015464B2 (de) |
| AT (2) | ATE256143T1 (de) |
| AU (1) | AU4684993A (de) |
| CA (1) | CA2140428C (de) |
| DE (2) | DE69333842T2 (de) |
| WO (1) | WO1994002501A1 (de) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5955591A (en) * | 1993-05-12 | 1999-09-21 | Imbach; Jean-Louis | Phosphotriester oligonucleotides, amidites and method of preparation |
| ATE177430T1 (de) * | 1993-05-12 | 1999-03-15 | Novartis Erfind Verwalt Gmbh | Nukleoside und oligonukleotide mit 2'- ethergruppen |
| AT407639B (de) * | 1993-12-13 | 2001-05-25 | Christian Dr Noe | Modifizierte oligonukleotide, verfahren zu ihrer herstellung und verwendung als wirkstoffe zur herstellung von arzneimitteln |
| US5756707A (en) * | 1994-12-13 | 1998-05-26 | Perseptive Biosystems, Inc. | Method of making 2'-O-alkyl pyrimidine ribonucleosides |
| US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
| BR9707529A (pt) | 1996-02-14 | 2000-01-04 | Isis Pharmaceuticals Inc | Oligunucleotìdeo especificamente hibridizável com dna ou rna. |
| JP2000512630A (ja) * | 1996-06-06 | 2000-09-26 | ノバルティス アクチエンゲゼルシャフト | ２’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体 |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US6130038A (en) | 1996-07-16 | 2000-10-10 | Gen-Probe Incorporated | Method for amplifying target nucleic acids using modified primers |
| US7070925B1 (en) | 1996-07-16 | 2006-07-04 | Gen-Probe Incorporated | Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe |
| US6025133A (en) * | 1996-12-30 | 2000-02-15 | Gen-Probe Incorporated | Promoter-sequestered oligonucleoside and method of use |
| US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
| US6576752B1 (en) * | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
| US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| DE19741715A1 (de) * | 1997-09-22 | 1999-03-25 | Hoechst Ag | Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung |
| US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
| US6673912B1 (en) | 1998-08-07 | 2004-01-06 | Isis Pharmaceuticals, Inc. | 2′-O-aminoethyloxyethyl-modified oligonucleotides |
| US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
| AU6071300A (en) * | 1999-07-06 | 2001-01-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides incorporating both 2-aminoadenine and 5-substituted pyrimidines |
| US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
| JP3596669B2 (ja) * | 2000-08-08 | 2004-12-02 | ヤマサ醤油株式会社 | ２’−ｏ−アルキルグアノシンの製造法 |
| CA2451643C (en) | 2001-06-21 | 2012-11-13 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
| US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
| US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
| AU2002334895B2 (en) | 2001-10-09 | 2006-10-19 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| EP1549767A4 (de) | 2002-09-26 | 2006-06-07 | Amgen Inc | Modulation der expression von forkhead-box o1a |
| AU2003295387A1 (en) | 2002-11-05 | 2004-06-03 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| JP4986109B2 (ja) | 2002-11-13 | 2012-07-25 | ジェンザイム・コーポレーション | アポリポタンパク質ｂ発現のアンチセンス調節 |
| PT2336318E (pt) | 2002-11-13 | 2013-06-12 | Genzyme Corp | Modulação anti-sentido da expressão de apolipoproteína b |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| JP2009531283A (ja) | 2006-02-02 | 2009-09-03 | アラーガン、インコーポレイテッド | 眼系疾患の処置のための組成物および方法 |
| DE102006017600A1 (de) * | 2006-02-09 | 2007-08-16 | Friedel, Ruthard, Dr. | Nucleosidanaloga als Genexpressionsregulatoren bei Viren |
| EP1820804A1 (de) * | 2006-02-20 | 2007-08-22 | Humboldt-Universität zu Berlin | Lipophile Oligonukleotide |
| WO2007119624A1 (ja) * | 2006-04-13 | 2007-10-25 | National University Corporaton Hokkaido University | 抗ヘルペスウイルス活性を有するヌクレオシド誘導体 |
| EP4082551A1 (de) | 2006-08-08 | 2022-11-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Struktur und verwendung von 5'-phosphat-oligonukleotiden |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| EP2297323A1 (de) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon |
| EP2508530A1 (de) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags |
| SG10201610936RA (en) | 2011-12-22 | 2017-02-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP2712870A1 (de) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Neuartige RIG-I-Liganden und Herstellungsverfahren dafür |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
| AU2015327836B2 (en) | 2014-10-03 | 2021-07-01 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| EP3390636B1 (de) | 2015-12-14 | 2021-05-19 | Cold Spring Harbor Laboratory | Antisense-oligomere zur behandlung von dravet-syndrom |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| EP3673080B1 (de) | 2017-08-25 | 2023-10-18 | Stoke Therapeutics, Inc. | Antisense-oligomere zur behandlung von leiden und krankheiten |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| MX2020011570A (es) | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Administracion extrahepatica. |
| CN108822174A (zh) * | 2018-08-29 | 2018-11-16 | 上海兆维科技发展有限公司 | 新型核苷修饰物2’-eoe-鸟嘌呤核苷及其制备方法 |
| CN113748209A (zh) | 2019-02-27 | 2021-12-03 | 斯托克制药公司 | 用于治疗病况和疾病的反义寡聚体 |
| EP4065715A4 (de) * | 2019-11-27 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Synthese von 3'-rna oligonukleotiden |
| AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU651569B2 (en) | 1990-01-11 | 1994-07-28 | Isis Pharmaceuticals, Inc. | Compositions and methods for detecting and modulating RNA activity and gene expression |
| DE4037363A1 (de) | 1990-04-09 | 1991-10-10 | Europ Lab Molekularbiolog | 2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten |
| DE4110085A1 (de) * | 1991-03-27 | 1992-10-01 | Boehringer Ingelheim Int | 2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide |
| US5214135A (en) * | 1991-08-30 | 1993-05-25 | Chemgenes Corporation | N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides |
-
1993
- 1993-07-20 EP EP93917287A patent/EP0651759B1/de not_active Expired - Lifetime
- 1993-07-20 WO PCT/US1993/006807 patent/WO1994002501A1/en not_active Ceased
- 1993-07-20 AU AU46849/93A patent/AU4684993A/en not_active Abandoned
- 1993-07-20 EP EP02076058A patent/EP1223173B1/de not_active Expired - Lifetime
- 1993-07-20 AT AT93917287T patent/ATE256143T1/de not_active IP Right Cessation
- 1993-07-20 DE DE69333842T patent/DE69333842T2/de not_active Expired - Lifetime
- 1993-07-20 DE DE69333344T patent/DE69333344T2/de not_active Expired - Lifetime
- 1993-07-20 JP JP6504646A patent/JP3015464B2/ja not_active Expired - Lifetime
- 1993-07-20 CA CA002140428A patent/CA2140428C/en not_active Expired - Lifetime
- 1993-07-20 AT AT02076058T patent/ATE299509T1/de not_active IP Right Cessation
-
1997
- 1997-07-18 JP JP9194153A patent/JPH1087689A/ja active Pending
-
1999
- 1999-10-15 JP JP11293153A patent/JP2000095793A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69333344D1 (de) | 2004-01-22 |
| JP2000095793A (ja) | 2000-04-04 |
| CA2140428C (en) | 2003-07-08 |
| CA2140428A1 (en) | 1994-02-03 |
| DE69333842T2 (de) | 2006-04-27 |
| EP1223173A3 (de) | 2003-04-16 |
| JPH1087689A (ja) | 1998-04-07 |
| WO1994002501A1 (en) | 1994-02-03 |
| ATE299509T1 (de) | 2005-07-15 |
| EP0651759B1 (de) | 2003-12-10 |
| JPH07508042A (ja) | 1995-09-07 |
| DE69333344T2 (de) | 2004-10-07 |
| EP0651759A1 (de) | 1995-05-10 |
| EP0651759A4 (de) | 1995-10-25 |
| EP1223173B1 (de) | 2005-07-13 |
| JP3015464B2 (ja) | 2000-03-06 |
| DE69333842D1 (de) | 2005-08-18 |
| EP1223173A2 (de) | 2002-07-17 |
| AU4684993A (en) | 1994-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE256143T1 (de) | 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen | |
| HUT62010A (en) | Process for producing oligonucleotide analogs comprising terminal 3 - 3, or 5 - 5- intermolecular bonds | |
| GB2228479B (en) | 2',3'-dideoxy purine nucleosides and process for the preparation thereof | |
| DE3853060D1 (de) | Verfahren zur Herstellung von Oligonucleotiden. | |
| HU206683B (en) | Process for producing 1,5-diphenyl-pyrazolo-3-carboxylic acid derivatives and selective herbicide compositions containing them as antidotum | |
| IT1237253B (it) | Imbragatura dorsale morbida per il supporto delle bombole d'aria per sommozzatori. | |
| EP0266168A3 (de) | Zusammensetzungen und Verfahren zur Herstellung von Oligonukleotiden, deren 5' Ende phosphoryliert ist | |
| FI885153A0 (fi) | Menetelmä terapeuttisesti aktiivisten 2',3'-dideoksi-2'-fluorinukleosidien valmistamiseksi | |
| EP0282989A3 (en) | Process for producing 5'-inosinic acid | |
| DE3861825D1 (de) | Verfahren zur herstellung von (2,2)-paracyclophan. | |
| FI885094A7 (fi) | Menetelmä terapeuttisesti käyttökelpoisen 2',3'-dideoksi-3'-fluoripyrimidiini- tai -puriininukleosidin valmistamiseksi | |
| FI881413A7 (fi) | Menetelmä 3'-atsido-3'-deoksitymidiinin valmistamiseksi. | |
| EP0251489A3 (en) | Process for producing 5'-guanylic acid | |
| IL110968A0 (en) | Nucleosides, nucleotides and oligonucleotides comprising tris-4,4',4"-tert-butylphenylmethyl, as protected group and their preparation | |
| IE45285L (en) | Polyribonucleotides. | |
| EP0521463A3 (en) | Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents | |
| DE59004582D1 (de) | 1,3-Di-arylmethoxy-4,6-dinitrobenzole, Verfahren zu ihrer Herstellung und Verfahren zur Herstellung von 4,6-Diaminoresorcin. | |
| DE68922507D1 (de) | Verfahren zur Herstellung von beta-2',2'-Difluornukleosiden. | |
| DE3887212D1 (de) | Verfahren zur Herstellung von Derivaten von 6,7-Diazyl-7-desacetylforskolin. | |
| DE3874496D1 (de) | Verfahren zur herstellung von 4,4'-dibrombiphenyl. | |
| DE69206765D1 (de) | Verfahren zur herstellung von 2',3'-dideoxy-beta-nucleosiden | |
| DE3889248D1 (de) | Verfahren zu Herstellung von Purinverbindungen. | |
| DE3887293D1 (de) | Si, Si'-Diorganyl-N-alkyl-tetrachlor-disilazane und Verfahren zu ihrer Herstellung. | |
| IL93001A0 (en) | Purine nucleosides and nucleotides,processes for the preparation thereof and pharmaceutical compositions containing the same | |
| DE3887710D1 (de) | 1-(3,5-Di-0-benzoyl-2-deoxy-beta-D-threo-pentofuranosyl)Thymine und Verfahren zu deren Herstellung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |